Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:hydromorphone
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02AA03
|
| gptkbp:contraindication |
patients with known or suspected gastrointestinal obstruction
opioid non-tolerant patients patients with acute or severe bronchial asthma patients with significant respiratory depression |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:form |
extended-release tablet
|
| gptkbp:halfLife |
11 hours (approximate)
|
| https://www.w3.org/2000/01/rdf-schema#label |
Exalgo
|
| gptkbp:indication |
management of moderate to severe pain in opioid-tolerant patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Mallinckrodt_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Hydromorphone
|
| gptkbp:bfsLayer |
7
|